Sanj.Bo
Sanj BO is a pharmaceutical company that generates revenue primarily through the development, manufacturing, and sale of prescription and over-the-counter drugs.
Business. Sanj BO is a pharmaceutical company that generates revenue primarily through the development, manufacturing, and sale of prescription and over-the-counter drugs.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Sanj BO is a pharmaceutical company that generates revenue primarily through the development, manufacturing, and sale of prescription and over-the-counter drugs.
Sanj BO maintains a relatively conservative capital structure, with a debt-to-equity ratio of 0.21, indicating a low reliance on debt financing. The company's liquidity position is assessed as medium, with a current ratio of 1.08, suggesting it has just enough current assets to cover its short-term liabilities. However, the company's net cash position is negative after subtracting total debt, which could signal potential liquidity constraints in the near term.
In terms of profitability, Sanj BO reports a return on equity (ROE) of 21.3% and a return on assets (ROA) of 10.35%, both of which are strong indicators of efficient capital utilization and asset management. These metrics suggest the company is generating solid returns relative to its equity and asset base, which is favorable compared to the industry's typical performance benchmarks.
The company's revenue is concentrated in the pharmaceuticals segment, with no disclosed geographic diversification in the provided data. This lack of geographic segmentation implies that Sanj BO's performance is likely tied to a single or limited number of markets, which could expose it to regional economic or regulatory risks.
Looking ahead, Sanj BO's growth trajectory appears to be constrained in the short term, as the company reported negative free cash flow of INR -216.33 million and capital expenditures of INR -303.49 million. These figures suggest that the company is investing heavily in its operations, which may impact near-term profitability but could support long-term growth.
The company's risk profile is characterized by medium liquidity risk and low dilution risk. The negative net cash position after debt is a key flag, indicating that the company may need to raise additional capital or manage its working capital more effectively to maintain liquidity. However, the absence of significant dilution risk suggests that the company is not currently issuing new shares at a rate that would significantly dilute existing shareholders.
There are no recent events or filings disclosed in the provided data that would indicate material changes in the company's operations or financial position.
- Sanj BO maintains a strong ROE of 21.3% and ROA of 10.35%, indicating efficient use of capital and assets.
- The company's debt-to-equity ratio of 0.21 suggests a conservative capital structure with limited leverage.
- Free cash flow is negative at INR -216.33 million, indicating significant reinvestment in the business.
- The company's liquidity position is medium, with a current ratio of 1.08 and a negative net cash position after debt.
- Revenue is concentrated in the pharmaceuticals segment, with no geographic diversification disclosed.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- SANJ.BO Market data — financials · 2026-05-29